Baidu
map

SCI TRANSL MED:肺泡巨噬细胞可能是影响慢性阻塞性肺疾病治疗的罪魁祸首

2017-06-23 cailingrui MedSci原创

慢性阻塞性肺疾病(COPD)是一种气道炎症和肺组织损伤的疾病,同样是导致世界范围内人类死亡的一大诱因。在健康的气道中,肺泡巨噬细胞(AMs)相对静止,以避免对各个暴露抗原的炎症反应,这对于气道和环境的稳定的相互作用至关重要。在慢性阻塞性肺疾病中,肺泡巨噬细胞数量会增加并产生更多的促炎介质,有助于肺组织的损伤和炎症。 慢性阻塞性肺疾病患者更容易受到细菌性呼吸道感染,导致肺炎和病情恶化,相应的增加发病

慢性阻塞性肺疾病(COPD)是一种气道炎症和肺组织损伤的疾病,同样是导致世界范围内人类死亡的一大诱因。在健康的气道中,肺泡巨噬细胞(AMs)相对静止,以避免对各个暴露抗原的炎症反应,这对于气道和环境的稳定的相互作用至关重要。在慢性阻塞性肺疾病中,肺泡巨噬细胞数量会增加并产生更多的促炎介质,有助于肺组织的损伤和炎症。 慢性阻塞性肺疾病患者更容易受到细菌性呼吸道感染,导致肺炎和病情恶化,相应的增加发病率和死亡率。慢性阻塞性肺疾病患者易感性增加的原因还未阐明,但已经有研究显示,在慢性阻塞性肺疾病患者中,肺泡巨噬细胞吞噬细菌的能力受损。

Bewley等人对COPD患者的肺泡巨噬细胞的抗菌功能做了进一步探索。与之前的研究结果一致,他们发现与健康肺泡巨噬细胞相比,世代培养的COPD肺泡巨噬细胞会产生更多的线粒体活性氧(mROS),与健康的肺泡巨噬细胞相比,这是杀死微生物的必要应答反应。接下来,他们专注于急性感染,并进一步研究表明,COPD肺泡巨噬细胞受损并延缓微生物应答反应,还与急性肺炎球菌感染后不能增加mROS产生有关。他们发现,延缓细菌杀伤的抗凋亡蛋白的Mcl-1在COPD患者肺泡巨噬细胞中表达量增加。此外,Mcl-1 +鼠转基因巨噬细胞在急性肺炎球菌感染反应中表现出微生物杀伤功能受损和mROS产物降低的现象,这表明该缺陷可能是Mcl-1依赖性的。

即使除去了最初引起疾病的刺激物(例如香烟烟雾),COPD患者的呼吸道也受到慢性炎症,细菌定植和抗急性感染的能力下降的困扰。了解这种独特的环境如何损害自体防能力,对确定更好的治疗方案至关重要。


原始出处:
Stephanie A. Christenson. Flipping the kill switch. Sci Transl Med . 21 Jun 2017:Vol. 9, Issue 395, eaan6192

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1661141, encodeId=28c9166114101, content=<a href='/topic/show?id=00658214552' target=_blank style='color:#2F92EE;'>#肺泡巨噬细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82145, encryptionId=00658214552, topicName=肺泡巨噬细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc725200310, createdName=kkunny, createdTime=Sat Mar 10 04:16:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982766, encodeId=64f81982e6686, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat Dec 02 18:16:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067240, encodeId=9636206e24036, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Mar 26 13:16:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656810, encodeId=936f16568109c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Mar 04 12:16:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696734, encodeId=61bd1696e3411, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Tue Aug 08 17:16:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607703, encodeId=4b83160e7032f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 24 20:16:00 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1661141, encodeId=28c9166114101, content=<a href='/topic/show?id=00658214552' target=_blank style='color:#2F92EE;'>#肺泡巨噬细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82145, encryptionId=00658214552, topicName=肺泡巨噬细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc725200310, createdName=kkunny, createdTime=Sat Mar 10 04:16:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982766, encodeId=64f81982e6686, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat Dec 02 18:16:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067240, encodeId=9636206e24036, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Mar 26 13:16:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656810, encodeId=936f16568109c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Mar 04 12:16:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696734, encodeId=61bd1696e3411, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Tue Aug 08 17:16:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607703, encodeId=4b83160e7032f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 24 20:16:00 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1661141, encodeId=28c9166114101, content=<a href='/topic/show?id=00658214552' target=_blank style='color:#2F92EE;'>#肺泡巨噬细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82145, encryptionId=00658214552, topicName=肺泡巨噬细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc725200310, createdName=kkunny, createdTime=Sat Mar 10 04:16:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982766, encodeId=64f81982e6686, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat Dec 02 18:16:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067240, encodeId=9636206e24036, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Mar 26 13:16:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656810, encodeId=936f16568109c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Mar 04 12:16:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696734, encodeId=61bd1696e3411, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Tue Aug 08 17:16:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607703, encodeId=4b83160e7032f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 24 20:16:00 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1661141, encodeId=28c9166114101, content=<a href='/topic/show?id=00658214552' target=_blank style='color:#2F92EE;'>#肺泡巨噬细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82145, encryptionId=00658214552, topicName=肺泡巨噬细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc725200310, createdName=kkunny, createdTime=Sat Mar 10 04:16:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982766, encodeId=64f81982e6686, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat Dec 02 18:16:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067240, encodeId=9636206e24036, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Mar 26 13:16:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656810, encodeId=936f16568109c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Mar 04 12:16:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696734, encodeId=61bd1696e3411, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Tue Aug 08 17:16:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607703, encodeId=4b83160e7032f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 24 20:16:00 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
    2018-03-04 bsmagic9140
  5. [GetPortalCommentsPageByObjectIdResponse(id=1661141, encodeId=28c9166114101, content=<a href='/topic/show?id=00658214552' target=_blank style='color:#2F92EE;'>#肺泡巨噬细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82145, encryptionId=00658214552, topicName=肺泡巨噬细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc725200310, createdName=kkunny, createdTime=Sat Mar 10 04:16:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982766, encodeId=64f81982e6686, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat Dec 02 18:16:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067240, encodeId=9636206e24036, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Mar 26 13:16:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656810, encodeId=936f16568109c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Mar 04 12:16:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696734, encodeId=61bd1696e3411, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Tue Aug 08 17:16:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607703, encodeId=4b83160e7032f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 24 20:16:00 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
    2017-08-08 tomyang96
  6. [GetPortalCommentsPageByObjectIdResponse(id=1661141, encodeId=28c9166114101, content=<a href='/topic/show?id=00658214552' target=_blank style='color:#2F92EE;'>#肺泡巨噬细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82145, encryptionId=00658214552, topicName=肺泡巨噬细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc725200310, createdName=kkunny, createdTime=Sat Mar 10 04:16:00 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982766, encodeId=64f81982e6686, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat Dec 02 18:16:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067240, encodeId=9636206e24036, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Mar 26 13:16:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656810, encodeId=936f16568109c, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Mar 04 12:16:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696734, encodeId=61bd1696e3411, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Tue Aug 08 17:16:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607703, encodeId=4b83160e7032f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 24 20:16:00 CST 2017, time=2017-06-24, status=1, ipAttribution=)]

相关资讯

慢性阻塞性肺病初始治疗:LABA VS 噻托溴铵

2017年1月,发表在《Chest》的一项由加拿大科学家进行的基于人群的比较性安全性研究考察了慢性阻塞性肺病(COPD)中,长效支气管扩张剂的起始和不良心肺事件的风险。

盘点:近期慢性阻塞性肺疾病重要研究进展一览

慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)是一种可导致患者呼吸功能逐渐下降的慢性肺部疾病,该疾病与气道的气流持续性受限和肺脏对有毒颗粒或气体的慢性炎性反应增强有关,急性加重和并发症影响着疾病的严重程度和对个体的预后。由于COPD是全世界范围内发病率和死亡率最高的疾病,引起了社会各界的广泛重视。这里梅斯小编整理了今年以来关于慢性阻塞性

Respir Med:阿地溴铵/福莫特罗混合剂的长期安全性和耐受性

2017年4月,发表在《Respir Med》的一项由加拿大、英国、美国和西班牙科学家进行的随机、III期、双盲、安慰剂对照、为期6个月的AUGMENT延期研究考察了阿地溴铵/福莫特罗400/12μg用于中度至重度慢性阻塞性肺疾病(COPD)的长期安全性和耐受性。

精华专题:远离慢阻肺,让呼吸更畅快!内附白春学教授视频:

慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)是一种可导致患者呼吸功能逐渐下降的慢性肺部疾病,该疾病与气道的气流持续性受限和肺脏对有毒颗粒或气体的慢性炎性反应增强有关,急性加重和并发症影响着疾病的严重程度和对个体的预后。由于COPD是全世界范围内发病率和死亡率最高的疾病,引起了社会各界的广泛重视。为了让更多的临床医生了解指南中对COPD的筛

阿斯利康与Circassia合作开发2种慢性阻塞性肺病(COPD)药物

英国制药巨头阿斯利康(AstraZeneca)近日宣布,与英国制药公司Circassia Pharma达成一项战略合作协议,在美国市场开发和商业化Tudorza和Duaklir,这是2款吸入性呼吸药物,用于治疗慢性阻塞性肺病(COPD);其中,Tudorza已于2012年获美国FDA批准并已上市销售,Duaklir预计将于2018年

精品指南:2017 GOLD慢性阻塞性肺疾病全球倡议解读,全新专家解读视频免费送!

慢性阻塞性肺疾病全球倡议组织最新发布了2017版GOLD慢阻肺诊断治疗和预防的全球策略报告,文章包括对已经发布的2015版和2016版的更新。更新主要包括6部分内容。 【指南全文】 2017 GOLD慢性阻塞性肺疾病全球倡议:COPD诊断、治疗与预防全球策略 【指南解读】 自从2001年慢性阻塞性肺疾病全球倡议(GOLD)颁布第1版慢性阻塞性肺疾病诊断、处理和预防全球策

Baidu
map
Baidu
map
Baidu
map